# Randomized, Single-blinded, Multicenter Trial Comparing the Immune Response to a 2nd Booster Dose of COVID-19 mRNA Vaccine (Pfizer-BioNTech) or Sanofi /GSK B.1.351 Adjuvanted Vaccine in Adults

> **NCT05405283** · PHASE3 · UNKNOWN · sponsor: **Assistance Publique - Hôpitaux de Paris** · enrollment: 189 (actual)

## Conditions studied

- COVID-19 Vaccines

## Interventions

- **BIOLOGICAL:** 2nd booster with Comirnaty® (Pfizer-BioNTech)
- **BIOLOGICAL:** CoV2 preS dTM adjuvanted vaccine (B.1.351), Sanofi/GSK

## Key facts

- **NCT ID:** NCT05405283
- **Lead sponsor:** Assistance Publique - Hôpitaux de Paris
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2022-06-08
- **Primary completion:** 2022-07-15
- **Final completion:** 2023-07
- **Target enrollment:** 189 (ACTUAL)
- **Last updated:** 2023-07-03

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05405283

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05405283, "Randomized, Single-blinded, Multicenter Trial Comparing the Immune Response to a 2nd Booster Dose of COVID-19 mRNA Vaccine (Pfizer-BioNTech) or Sanofi /GSK B.1.351 Adjuvanted Vaccine in Adults". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT05405283. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*